Rice Hall James & Associates LLC Buys 18,609 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Rice Hall James & Associates LLC increased its stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 3.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 596,431 shares of the company’s stock after buying an additional 18,609 shares during the quarter. Kiniksa Pharmaceuticals International accounts for 1.4% of Rice Hall James & Associates LLC’s investment portfolio, making the stock its 22nd largest holding. Rice Hall James & Associates LLC owned 0.79% of Kiniksa Pharmaceuticals International worth $24,603,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Smartleaf Asset Management LLC purchased a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at about $36,000. EverSource Wealth Advisors LLC increased its stake in Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after buying an additional 532 shares during the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at about $41,000. CIBC Private Wealth Group LLC purchased a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at about $41,000. Finally, Quarry LP purchased a new stake in Kiniksa Pharmaceuticals International in the 3rd quarter valued at about $44,000. Institutional investors own 53.95% of the company’s stock.

Wall Street Analyst Weigh In

KNSA has been the subject of several analyst reports. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research note on Monday, May 4th. Wedbush increased their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the company an “outperform” rating in a research note on Wednesday, April 29th. Weiss Ratings upgraded shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, June 8th. Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research note on Monday, May 18th. Finally, Jefferies Financial Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $60.86.

Insider Activity

In other news, COO Ross Moat sold 2,367 shares of the company’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $48.58, for a total transaction of $114,988.86. Following the transaction, the chief operating officer owned 12,029 shares of the company’s stock, valued at $584,368.82. This represents a 16.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 483,654 shares of the company’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $51.86, for a total value of $25,082,296.44. Following the transaction, the chief executive officer directly owned 431,904 shares in the company, valued at $22,398,541.44. This represents a 52.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 653,301 shares of company stock worth $34,046,073. 51.98% of the stock is owned by company insiders.

Kiniksa Pharmaceuticals International Stock Up 0.9%

Kiniksa Pharmaceuticals International stock opened at $52.34 on Tuesday. Kiniksa Pharmaceuticals International, plc has a twelve month low of $26.27 and a twelve month high of $59.87. The firm has a 50 day moving average price of $50.57 and a 200-day moving average price of $46.03. The company has a market capitalization of $4.03 billion, a P/E ratio of 58.16 and a beta of 0.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The firm had revenue of $214.27 million for the quarter, compared to analysts’ expectations of $206.11 million. During the same quarter in the prior year, the firm earned $0.11 EPS. The business’s revenue for the quarter was up 55.5% compared to the same quarter last year. Equities analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.24 EPS for the current fiscal year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.